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Abstract 
Triacylglycerols (TAG) constitute the main energy storage resource in mammals, by virtue of their 
high energy density. This in turn is a function of their highly reduced state and hydrophobicity. 
Limited water solubility, however, imposes specific requirements for delivery and uptake 
mechanisms on TAG-utilising tissues, including the heart, as well as intracellular disposition. TAGs 
constitute potentially the major energy supply for working myocardium, both through blood-
borne provision and as intracellular TAG within lipid droplets, but also provide the heart with fatty 
acids (FA) which the myocardium cannot itself synthesise but are required for glycerolipid 
derivatives with (non-energetic) functions, including membrane phospholipids and lipid signalling 
molecules. Furthermore they serve to buffer potentially toxic amphipathic fatty acid derivatives. 
Intracellular handling and disposition of TAGs and their FA and glycerolipid derivatives similarly 
requires dedicated mechanisms in view of their hydrophobic character. Dysregulation of utilisation 
can result in inadequate energy provision, accumulation of TAG and/or esterified species, and 
these may be responsible for significant cardiac dysfunction in a variety of disease states. This 
review will focus on the role of TAG in myocardial energy provision, by providing FAs from 
exogenous and endogenous TAG sources for mitochondrial oxidation and ATP production, and 
how this can change in disease and impact on cardiac function. 
 
 
 
 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
3 
 
Key words: 
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Highlights: 
x Triacylglycerols are supplied to the myocardium within chylomicrons and VLDL 
x Heart assimilates triacylglycerol-rich lipoproteins by LPL and receptor-mediated routes 
x Exogenous triacylglycerol-derived fatty acids enter an intracellular lipid pool 
x Intracardiac triacylglycerol is an important source of fatty acids for oxidation 
x Dysregulation of triacylglycerol metabolism is associated with cardiac dysfunction 
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Abbreviations: 
Apo  apolipoprotein 
ATGL  adipose triacylglycerol lipase 
CM  chylomicron 
DGAT  diacylglycerol acyltransferase 
FA  fatty acid 
FABP  fatty acid binding protein 
FAT  fatty acid translocase 
FATP  fatty acid transport protein 
GPAT  glycerol phosphate acyltransferase 
H-LPL  heart lipoprotein lipase 
KO  knockout 
LD  lipid droplet 
LPL  lipoprotein lipase 
mTAG  myocardial triacylglycerol 
NEFA  non-esterified fatty acid 
PPAR  peroxisome proliferator-activated receptor 
STZ  streptozotocin 
TAG  triacylglycerol 
TGRLP  triacylglycerol-rich lipoprotein 
VLDL  very-low-density lipoprotein 
VLDLR  very-low-density lipoprotein receptor 
ZDF  Zucker diabetic fatty 
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1. Introduction 
The heart assimilates lipids from the plasma avidly. The myocardium has a high and unremitting 
demand for energy, and early studies suggest that cardiac ATP synthesis is derived principally from 
glucose utilisation (about 30%) and FA oxidation (about 70%)(see [1]. The FAs may be supplied as 
non-esterified FA (NEFA), originating principally from adipose tissue lipolysis (though with some 
ĚĞƌŝǀĞĚĨƌŽŵ “ƐƉŝůůŽǀĞƌ ?through the action of lipoprotein lipase (LPL)) or as TAG available in the 
hydrophobic cores of the TAG-rich lipoproteins (TGRLP): chylomicrons (CM), synthesised in the 
intestine from exogenous (dietary) fat, and very-low-density lipoprotein (VLDL), synthesised by the 
liver from endogenous lipid (derived in part from de novo lipogenesis of FA). Plasma TAG 
concentration is highly variable: fasting plasma [TAG] is typically ~ 0.6-0.7mM, increasing to > 1.5-
3.0mM following a mixed meal. By contrast, plasma [NEFA] is typically ~ 0.3mM, although it rises 
in markedly in fasting (and diabetes), an effect partly compensated by the accompanying 
increased tissue uptake. Since TAG yields 3xFA upon complete hydrolysis, plasma TAG-FA 
availability greatly (>90%) exceeds NEFA availability. The heart also contains significant amounts of 
TAG within lipid droplets (LD). However, defining myocardial preference for lipids has proved 
difficult. Cardiac substrate utilisation changes depending on plasma availability, and in disease, but 
maladaptive substrate utilisation by the heart may itself cause cardiac dysfunction. The question 
therefore is the extent to which TAGs are efficient myocardial energy providers, and necessary for 
optimal cardiac function.  
2. Myocardial exogenous triacylglycerol utilisation 
2.1. Cardiac chylomicron-TAG utilisation 
Measurement of TGRLP utilisation by the heart in vivo is technically challenging, but estimates of 
myocardial TAG-FA uptake generally support substantial cardiac CM-TAG utilisation.  
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Arterio-venous (A-V) differences measured by coronary sinus sampling are small, and early studies 
measuring total FA (NEFA + TAG-FA) across the human heart found that significant amounts of 
TAGs were extracted by the myocardium, and indirectly (by calculated difference) estimated that 
about half of the FAs utilised were TAG-derived (esterified). Subsequent A-V studies on non-
diabetic humans found that TAG-emulsion accounted for only ~ 17% of cardiac FA uptake; 
moreover, the heart accounted for only 3% of systemic TAG uptake [2]. Studies in dog heart found 
that 56% myocardial oxygen consumption (mVO2) was accounted for by total (NEFA+TAG) FA 
oxidation, of which 71% was calculated to be from TAG (hence about 40% of mVO2 was TAG 
oxidation)[3].  
Early experiments with rodents in vivo reported substantial cardiac uptake of labelled CM-TAG 
(more than any tissue examined besides liver)[4], and substantial CM-TAG oxidation was observed 
in rat heart, related to cardiac LPL activity; at physiological TAG concentrations (0.9mM) CM-TAG 
oxidation was able to provide about two-thirds of cardiac energy requirements [5]. Infusion of 
[
14
C]palmitate-labelled CM into rats demonstrated substantial CM-TAG oxidation which was 
decreased only slightly (16%) by co-administration of glucose, implying a preference for CM-TAG 
oxidation [6]. High rates of label retention of CM prepared from chyle lymph were found in heart 
(more than skeletal muscle though less than white adipose tissue), and about 3 fold higher than 
NEFA; the ratio of TAG retention to NEFA retention was higher in heart than other tissues, 
suggesting a strong cardiac preference for TAG [7]. Gousios [8] perfused rabbit hearts with 
d<1.006 lipoproteins containing labelled TAG (a density corresponding to both CM and VLDL) and 
found fractional extraction rates of 15% in the fed state and 30% in hearts from fasted animals. 
Significant cardiac utilisation of d<1.006 lipoprotein-TAG (CM) was also found in isolated rat heart 
[9]  ? TAG oxidation accounted for 40% of CO2 production (equivalent to that of NEFA 
oxidation)[10] (and in broad agreement with earlier studies [11]). Further evidence for a role for 
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CM-TAG in cardiac oxidative metabolism was the demonstration that CM increased mVO2 of 
perfused rat hearts, and decreased (halved) their glucose utilisation [12]. Interestingly, whilst 
oxygen is essential for metabolism, oxygen availability may not dictate uptake of CM-TAG. Indeed, 
high rates of TAG emulsion uptake (and LPL activity) in mouse heart in vivo were not affected by 
chronic intermittent hypoxia [13] suggesting a potential mismatch between CM-TAG uptake and 
utilisation. Mouse hearts perfused with rat CM (0.4mM) utilised large amounts of CM-TAG [14] 
and achieved high degrees of cardiac power; equal amounts of CM-TAG assimilated were oxidised 
and esterified into tissue lipids (mainly TAG) and CM-TAG oxidation rates were similar to NEFA 
(0.4mM palmitate) oxidation, though proportionately more NEFA was oxidised than esterified. 
Furthermore, NEFA did not inhibit CM-TAG utilisation by the mouse heart [14]. Rat hearts 
perfused with rat CM utilised CM-TAG to about the same extent as NEFA when each were 
compared as sole lipid substrates [15, 16] and CM could maintain cardiac mechanical function; 
most (83%) of the CM-TAG assimilated was oxidised, the remainder was esterified mostly into 
cellular TAG [15, 16]. NEFA did inhibit CM-TAG utilisation when co-perfused, and this was entirely 
due to decreased CM-TAG oxidation, but CM did not suppress myocardial NEFA uptake and 
metabolism [16]. Together, these observations imply that NEFA-derived FA are more likely to be 
oxidised and CM-TAG-derived FAs more likely to be esterified [14] suggesting that there may be 
discrete partitioning between non-esterified and CM-TAG-derived FA. Mouse hearts clear CM-TAG 
(by lipolysis) more rapidly than they assimilate core (cholesteryl ester) lipid: about 5% of injected 
CM were recovered in hearts within 2 min, indicating rapid CM uptake by this tissue, but 
deficiency in heart LPL (H-LPL) decreases CM binding  ? “ŵĂƌŐŝŶĂƚŝŽŶ ? ?to <1%, whilst mice that 
express LPL in heart alone doubled cardiac CM binding -  the amount of LPL expressed governing  
both CM binding and lipid assimilation [17]. Mice expressing LPL only in heart maintained 
essentially normal plasma TAG concentration and clearance, indicating both the importance of 
myocardial LPL for plasma TAG metabolism and the large cardiac utilisation of TGRLP [17, 18]. 
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Infusion of labelled CM-TAG into mice found that 80-90% of the TAG-FA was recovered from 
plasma, and TAG lipolysis contributed 10-20% of total plasma FA turnover [7]; given the 
substantial cardiac TAG-FA assimilation in these experiments, the authors proposed a model of 
very high local FA released from CM-TAG lipolysis [7]. dŚŝƐĐŽŶĐĞƉƚŽĨŚĞĂƌƚĂĐƚŝŶŐĂƐĂ “ƐŝŶŬ ?ĨŽƌ
CM-TAG is seen in physiologic and pathologic situations of metabolic perturbation and 
redistribution of plasma substrates. Perfused hearts from lactating rats showed a significant 
increase in NEFA utilisation but suppression of CM-TAG utilisation, consistent with decreased 
heparin-ƌĞůĞĂƐĂďůĞ>W>ĂĐƚŝǀŝƚǇĂŶĚ “ƌĞĚŝƌĞĐƚŝŽŶ ?ŽĨD-TAG away from heart and towards 
lactating mammary gland [19]. Hence, the heart does make a significant metabolic drain on CM-
TAG and this must be suppressed in the face of additional metabolic demand, e.g. from lactating 
mammary gland.  
Determining the role of CM-TAG in cardiac metabolism in disease states has also proved difficult. 
In diabetes, TGRLP, including CM, are structurally altered, and this may change their efficacy as 
substrates [20-23]. Myocardial lipid metabolism is also increased (and glucose utilisation 
suppressed) in diabetes (see [1, 24]), so both substrate and cellular factors are likely to be 
important. CM-TAG from streptozotocin (STZ)-diabetic rats were apo-E deficient, and cleared from 
the plasma of non-diabetic rats more slowly than control CM-TAG [20]; furthermore incubation of 
diabetic CM with HDL increased their apo-E content and increased their uptake by heart [20]. 
Similarly, slow (whole body) plasma clearance of TGRLP by STZ-diabetic rats in the fed state was 
reported [25]. There was no difference between STZ-diabetic and control rats in plasma clearance 
of normal CMs (though TAG clearance did depend on CM-TAG concentration administered) but 
there was a significant increase (trebling) in CM binding to diabetic rat cardiac endothelium [26], 
potentially reflecting aberrant energy requirement of the diabetic myocardium. Non-diabetic rat 
CM-TAG were oxidised 3.4-fold higher by STZ-diabetic mouse hearts, and 2.3-fold higher by db/db 
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(type 2 diabetic) mouse hearts, compared to control hearts, coupled with higher incorporation of 
CM-TAG into cellular lipids in both STZ-mouse hearts and db/db mouse hearts [27]. By 
comparison, NEFA oxidation in these experiments was about 3-fold higher than CM-TAG oxidation 
by control hearts (and hence comparable to CM-TAG oxidation by diabetic hearts)[27] suggesting a 
general dysregulation of fatty acid beta-oxidation in the absence of glucose uptake. STZ-diabetic 
rat hearts utilised rat CM-TAG to a greater extent (about 50% more) than control rat hearts, 
consistent with increased cardiac LPL activity [22], whilst STZ-diabetic rat CMs were utilised even 
more avidly by both diabetic and non-diabetic rat hearts (about doubled), suggesting 
functional/composition differences in STZ-CM [22]. Similar studies with type 2 diabetic Zucker 
(ZDF) rats found comparable results: diabetic hearts utilised diabetic CM to a greater extent than 
controls, due principally to increased TAG-FA oxidation rather than esterification of TAG-derived 
FA into cellular lipids [23], and was associated with increased LPL activity in diabetic hearts [23]. 
PET studies have also suggested that heart TAG utilisation and metabolism are increased in rat 
type 2 diabetes, coupled with impaired diastolic function [28]. Taken together, these observations 
suggest that increased cardiac reliance on lipid substrates in diabetes is accompanied by increased 
CM-TAG utilisation by the diabetic heart, possibly as a result of altered particle size/apolipoprotein 
composition and myocardial LPL status. 
2.2. Cardiac VLDL-TAG utilisation 
VLDL provides the major source of endogenous TAG supply to peripheral (extrahepatic) tissues 
although the physiological role of this substrate is contentious. In the well-fed state it certainly 
represents the major transport form of endogenous TAG-FA, synthesised by de novo hepatic 
lipogenesis and exported to adipose tissue for storage; however, in the post-absorptive state it is 
assembled in the liver from adipose-derived NEFA, and it is unclear why NEFA cannot supply FA 
direct to oxidative tissues such as heart. Indeed, this pathway certainly occurs, but the issue of the 
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respective roles of NEFA and VLDL-TAG in furnishing FA as metabolic substrate to the myocardium 
remains. VLDL are less efficient substrates for LPL than CM, by virtue of their lesser size and 
susceptibility to lipolysis [29]. Several studies have therefore examined the role of VLDL in cardiac 
TAG-FA provision, but these are technically difficult, requiring preparation and isolation of 
sufficient appropriately labelled, physiologically relevant, and species-specific VLDL particles to use 
in test systems. Artificial TAG emulsions more closely resemble CM; VLDLs have been prepared 
from donor plasma by centrifugation with labelling either by preinjection of FA, or post-isolation in 
vitro FA/TAG radiolabel transfer, or by liver perfusion. Unlike the episodic influx of CM, which 
increases the plasma TAG concentration by an order of magnitude in the post-absorptive  ? post-
prandial transition, plasma VLDL-TAG concentration is more constant (0.3-0.4mM).  
Studies of cardiac A-V (coronary sinus) differences in non-diabetic patients undergoing cardiac 
catheterisation (usually in the post-absorptive state) found that some hearts extracted plasma 
(VLDL)TAG but not others (as previously noted [30]) whilst infused labelled TAG was consistently 
extracted (extraction fraction ~11%)[2]. TAGs and NEFAs accounted for ~17% and ~83% 
respectively of myocardial FA uptake; myocardial spillover of lipolysis-derived FAs was 35%, 
suggesting that VLDL-TAG may be a minor contributor to energy production, but that luminal 
lipolysis may also release significant NEFA to the systemic circulation (see [7]). In this study the 
myocardium was only a minor contributor to total systemic TAG (VLDL) uptake (~3%) and systemic 
NEFA production (~0.5%)[2]. Previous studies had also suggested only limited VLDL-TAG utilisation 
by the human heart  ? with about 10-20% of cardiac energy deriving from VLDL [31]), suggesting 
that in human heart, at least in the postabsorptive state, NEFAs may be more important cardiac 
substrates than VLDL-TAG [30, 32]. Since human hearts can assimilate and oxidise large amounts 
of glucose when deprived of NEFA (and rodent hearts can function normally despite being LPL 
deficient [33]) these observations suggest that plasma VLDL-TAG is not an essential cardiac fuel. In 
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contrast to human studies, rat hearts perfused with rat plasma VLDL at physiological 
concentration (0.18mM) show substantial cardiac VLDL-TAG utilisation: ~40% of available VLDL-
TAG was utilised by 40 min and ~75% by 120 min [34] (although much lower rates of VLDL-TAG 
utilisation by isolated rat heart have also been reported under similar conditions [35]). High rates 
of VLDL-TAG utilisation by rat heart have also been reported (oxidation rate about 30nmol/min/g 
wet wt; about 60% of the VLDL-TAG utilised) [36]), with TAG-lipid removal  double that of 
125
I-
apoprotein assimilation [34], and in some studies even higher rates were found  ? about 60nmol 
TAG/min/g wet wt, representing >90% VLDL-TAG hydrolysis of [37]. Rat hearts also utilised human 
VLDL avidly [38, 39], and to the same extent as rat VLDL [39], suggesting that species selectivity 
may be less of an issue than previously considered. Synthetic VLDL-sized TAG emulsions 
administered intravenously to mice were only poorly assimilated by heart (about 5-fold less than 
adipose tissue or skeletal muscle), potentially reflecting the availability of apolipoproteins (though 
fractional catabolic rate increased with increasing particle size)[40]. Indeed, intestinal VLDL-TAG 
(iVLDL; isolated from chyle lipids of d<1.006 of fasted rats and lacking apoE and apoCII) was 
utilised by rat hearts [41], and oxidised at twice the rate of NEFA [42], but about half the rate of 
CM-TAG oxidation. Less iVLDL-TAG than NEFA was recovered in cellular lipids [42] suggesting 
greater partitioning towards oxidation. Rat VLDL prepared by rat liver perfusion was utilised by 
isolated rat hearts (~ 18nmol FA/min/g), but to a significantly lower extent than NEFA (~ 60nmol 
FA/min/g)) and CM (~ 75nmol FA/min/g) when each was compared as sole lipid substrate 
(0.4mM)[16]. This limited VLDL utilisation was not suppressed by NEFA when co-perfused, unlike 
CM utilisation which was decreased by NEFA [16], suggesting distinct pathways of utilisation. Of 
the VLDL-TAG-FA assimilated, about one quarter was incorporated into tissue lipids whilst the 
remainder was oxidised; by contrast, about 90% of CM-TAG was oxidised; the metabolic 
partitioning was not affected by NEFA [16]. Comparable results have also been reported [15, 22, 
23]. However, other authors demonstrate competition between NEFA and VLDL-TAG. Mouse 
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hearts perfused with human plasma VLDL or a synthetic TAG emulsion of similar size to CM utilised 
and oxidised TAG readily [43]; both VLDL and the CM-like emulsion decreased NEFA utilisation (by 
about half) and oxidation (by about 70%) and this effect was LPL-dependent [43]. These authors 
suggest that TGRLP-TAG is a major cardiac substrate and competes directly with NEFA utilisation, 
ƉƌŽƉŽƐŝŶŐĂ ‘ĐŽŵŵŽŶ ?FA pool within the cardiomyocyte. The concept of a single cardiomyocyte 
FA pool is supported by the demonstration that heart-specific LPL knockout (KO) mice have 
increased plasma [TAG] with decreased plasma TAG clearance and decreased cardiac VLDL uptake 
but unchanged [33] or even decreased [44] cardiac NEFA uptake, surprising in view of potential 
competition from FA originating in LPL-mediated TAG lipolysis [33]; the finding that NEFA 
oxidation is decreased (whilst glucose oxidation is increased) in LPL-KO mouse hearts infers that 
TAG and NEFA metabolism are interlinked. Whilst synthetic CM-like TAG emulsion is utilised by 
mouse heart more than liver, skeletal muscle or adipose tissue, only about half this rate was found 
with mouse VLDL injected into mice in vivo [45], whilst NEFA uptake is comparable to other 
tissues, implying that myocardial TAG utilisation exceeds that of NEFA [45]. Together, these 
findings support the notion that plasma TAG are a quantitatively important cardiac substrate, 
especially in view of the compromised cardiac function in heart-specific cardiac LPL-KO mice with 
accompanying impaired cardiac VLDL utilisation [44], though acute studies in isolated rat hearts 
failed to show a significant influence of TGRLPs on cardiac function [16]. The importance of plasma 
TAG as a muscle fuel was shown in mice overexpressing LPL in muscle alone: this rescues the 
global LPL-KO mice from neonatal (hyperlipidemic) death [46], normalising plasma VLDL [47]. In 
addition, mutant mice expressing LPL in cardiac muscle but not skeletal muscle or adipose tissue 
have normal plasma TAG [18], suggesting cardiac LPL alone can rescue lethal LPL-KO 
hypertriglyceridemia and demonstrating the importance of plasma TAG as a bulk cardiac substrate 
and of the heart in regulating plasma TAG. 
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The role of insulin in cardiac TGRLP metabolism has proved difficult to elucidate, reflecting the 
difficulty in defining the role of insulin in cardiac LPL regulation. Rat heart assimilation of VLDL-TAG 
was comparable to adipose tissue and skeletal muscle, and was not significantly affected by 
insulin, but hearts of functionally hepatectomised rats assimilated VLDL-TAG more rapidly [48]. 
STZ-diabetic rat hearts lipolysed intestinal VLDL-TAG (0.32mM) to less than half the extent of 
control hearts [21, 41]; this was reversible with insulin, suggesting LPL recruitment to capillary 
endothelium requires functional insulin [41]. Lipolysis of plasma VLDL-TAG prepared from STZ-
diabetic rats was only 63% that of plasma VLDL-TAG from non-diabetic animals [21] ? “ŝĂďĞƚŝĐ ?
VLDL perfused into diabetic hearts underwent lipolysis to less than a quarter of control VLDL in 
non-diabetic hearts [21], suggesting that both VLDL particle (composition) and myocardial factors 
are influenced by insulin. By contrast, Sambandam et al found that normal plasma VLDL (0.3mM 
TAG) was utilised at a significantly faster rate by STZ-diabetic rat hearts than controls [49], and 
associated with  increased LPL activity in the STZ-diabetic hearts [50]. VLDL-TAG metabolic rate in 
these studies was relatively low (control: 0.5nmol/min/heart) but comparable to other reports 
[21] whilst VLDL assimilation in diabetic heart was twice this rate (0.93nmol/min/heart)[49]. VLDL 
from perfused rat livers (0.4mM) showed similar results: STZ-diabetic hearts utilised about 50% 
more (control) VLDL-TAG than non-diabetic hearts. Interestingly, diabetic VLDL-TAG (from 
perfused STZ-diabetic rat livers) was utilised only poorly by control hearts, but diabetic hearts 
utilised diabetic VLDL-TAG comparably to control VLDL-TAG (and CM-TAG) [22].  As with CM, 
myocardial factors (uptake and disposal mechanisms) and lipoprotein factors (LP particle 
composition) are both likely to be important in diabetes. LPL regulation in diabetes has been 
recently reviewed [51]. Both glucocorticoids and insulin are essential for LPL translation [52]. 
Increased, unchanged, and decreased H-LPL activity have all been reported in diabetes; currently, 
at least in rodent models, the favoured paradigm is mediation of coronary luminal LPL by post-
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translational (?heparanase-mediated) mechanisms, with increased H-LPL in diabetes [22, 23] as a 
consequence of the hyperglycemia [53].  
VLDL utilisation in type 2 diabetes has also been examined. Micro-PET techniques in a rodent 
model of type 2 diabetes provided indirect evidence that increased myocardial FA oxidation was 
from plasma TAG rather than NEFA (although the specific contributions of VLDL and CM were not 
defined) [54]. ZDF-diabetic rat hearts utilised about 50% more VLDL-TAG prepared from ZDF rat 
liver perfusion than controls [23]; this increased utilisation was entirely accounted for by increased 
VLDL-TAG-FA oxidation with no increase in accumulation of myocardial lipids  [23], further 
supporting the phenotype-specific nature of both VLDL-TAG synthesis and its utilisation by heart.  
2.3. Cardiac TGRLP utilisation in disease 
The relationship between TGRLP metabolism and cardiac function is complex  ? cardiac substrate 
(including TAG) selection is altered in hypertrophy/failure, but changes in substrate utilisation can 
themselves lead to cardiac dysfunction/failure  ? the concepts of adaptive and maladaptive 
responses and lipotoxicity. Hypertrophy is characterised by chronic increase in cardiac work and 
hence energy requirement. The conventional paradigm is that hypertrophy and heart failure are 
accompanied by increased glucose, and decreased FA utilisation, with downregulation of fatty acid 
oxidation-related genes [1]. However, cardiac LPL activity (and hence continued supply of TGRLP-
FA for cardiac utilisation) are critical for the normal cardiac response to ɴ-agonist stimulation and 
hypertension [55]. Furthermore, LPL-KO hearts are susceptible to failure because of low TAG 
hydrolysis and despite increased glucose utilisation [44]. Increased FA (and TAG) delivery to the 
heart by high-fat diets is beneficial in rats with MI and pressure-overload cardiac dysfunction [56]. 
Cold acclimation, a chronic physiologic stimulus to increase cardiac work, causes hypertrophy and 
increases heart LPL (but not VLDL-R) activity in rats, with increased TAG uptake; the increased LPL 
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is not related to AMPK activation [57, 58] suggesting that both acute and chronic mechanisms for 
upregulation of LPL may be active.  
The composition of VLDL (apoprotein complement; lipid subclass content) varies in certain 
(metabolic) diseases, including diabetes [21], and sepsis [59]. Structurally variant VLDL synthesised 
by the liver in endotoxemia is a better substrate for myocardium (about double VLDL-TAG 
oxidation rate)[59]; furthermore, sepsis/endotoxemia is also associated with increased hepatic 
VLDL synthesis and secretion, increasing VLDL availability. Since cardiac work increased in 
increased in (early) sepsis as a result of the hyperdynamic circulation and augmented cardiac 
output, this may represent a mechanism to increase supply of endogenous lipid specifically to the 
working myocardium under these pathological conditions. 
3. Myocardial triacylglycerol uptake 
CM and VLDL TAG must enter the myocardium through specialised pathways. Two established 
routes of entry are 1. through lipolysis by lipoprotein lipase (EC 3.1.1.34) and 2. by particle or 
remnant particle uptake through lipoprotein receptors. Both pathways occur [15], but are 
functionally inter-relateĚƚŚƌŽƵŐŚ “ďƌŝĚŐŝŶŐ ?ŝŶƚĞƌĂĐƚŝŽŶƐĂƚƚŚĞĐŽƌŽŶĂƌǇĞŶĚŽƚŚĞůŝƵŵ ?hence their 
respective contributions to TAG (both CM and VLDL) uptake remain disputed. This may be a 
specious dispute. 
Bharadwaj et al [60] demonstrated the importance of lipolysis in TGRLP core lipid uptake, and 
using heart specific LPL-KO and CD36-KO mice they further demonstrated that VLDL-derived TAG-
FA entered the cell through a CD36-mediated channel (low capacity high affinity), whereas CM-
derived TAG-FA entered through a non-CD36-mediated route (possibly the lower affinity non-
ƐĂƚƵƌĂďůĞ ?ƌĞĐĞƉƚŽƌ “ĨůŝƉ-ĨůŽƉ ?ŵĞĐŚĂŶŝƐŵ ?dŚĞ details of TAG-FA channelling are however still 
uncertain (Fig. 1).   
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3.1. Lipoprotein lipase ʹ mediated myocardial TAG uptake 
Despite contributing less than 0.5% of total body mass, myocardium possesses 5% of total 
heparin-releasable LPL - LPL expression in the heart (H-LPL) is the highest (per g) of any tissue [61] 
suggesting 1. it is a quantitatively important mechanism of cardiac energy capture (sufficient for 
cardiac LPL activity to modulate circulating plasma TAG levels [33]) and 2. TAG must be an 
important cardiac oxidative fuel. LPL-mediated lipolysis is generally considered rate-limiting for 
tissue TAG utilisation. It has a complex cell biology which is not yet fully elucidated (see [51, 52, 
62]. The attachment of mature, active LPL to EC-ƐƵƌĨĂĐĞ,^W' ?'W/,W ?ĐŽŶƐƚŝƚƵƚĞƐĂ “ƉůĂƚĨŽƌŵĨŽƌ
ůŝƉŽůǇƐŝƐ ?[63] permitting plasma TAG hydrolysis [64]. As well as tissue uptake of the liberated FA, 
there is FA  “ƐƉŝůůŽǀĞƌ ?ŝŶƚŽƚŚĞƉůĂƐŵĂ [7]. In heart, a substantial proportion of LPL-released FA are 
assimilated by cardiomyocytes, through pathways that may or may not be shared with NEFA 
uptake mechanisms (e.g. CD36/FAT; FABP; FATP)[15, 60], but cardiac LPL may make a substantial 
contribution to plasma NEFA through luminal lipolysis of plasma lipoproteins. LPL regulation is 
highly tissue-specific, but its control in myocardium has proved difficult to define (see [51, 62]). 
The LPL gene has multiple upstream cis-acting regulatory elements  including PPRE, LXR, RXR, CT 
element, sterol regulatory element- ? ?/&Eɶ-responsive element and anterior protein-1 (AP-1)-like 
element (see [52]). Cardiac LPL appears inversely related to adipose LPL but does not vary so 
profoundly. However, two features of H-LPL regulation are clear: 1. it is related to cardiac energy 
status and 2. it is influenced by plasma-borne factors which may be associated with TGRLP 
particles. H-LPL increases on fasting [65], and decreases on refeeding [61](though to only relatively 
limited extents). AMPK stimulation increases H-LPL activity and increases cardiac TAG uptake [66, 
67]. It is likely that there is constitutive enzyme expression, perhaps reflecting the availability of 
VLDL-TAG regardless of nutritional status. Plasma TAG may modulate LPL and hence cardiac TAG 
assimilation [58, 68], and TGRLPs modified heparin-releasable H-LPL activity [16]. Other 
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glycerolipids can also regulate H-LPL activity: palmitoyl lyso-PC [69] and LPA [70] stimulate LPL 
translocation and activity. Cardiac LPL activity may be regulated directly: angptl-3 and angptl-4 are 
angiopoietin-like growth factor/cytokine related proteins secreted into plasma with pleiotropic 
effects, including inhibition of LPL [71]. Their expression changes with nutritional status - fasting 
induces cardiac angptl-4 [72, 73]. Loss of angptl-4 is associated with decreased plasma TAG 
through increased LPL-mediated clearance, whilst increased angptl-4 expression is associated with 
inhibited H-LPL and increased plasma TAG, together with cardiac dysfunction [74]. A similar 
mechanism has also been noted following high-fat feeding, which increases angptl-4 [58], 
suggesting a mechanism of cardiac LPL regulation in situ related to TAG-FA flux. However, chronic 
intermittent hypoxia has no effect on H-LPL activity or cardiac TAG uptake, despite inhibiting 
adipose LPL through upregulating angptl-4 [13]. Apolipoproteins also modify LPL activity directly: 
apo-CII is an obligatory activating co-factor of LPL whilst apo-CI and apo-CIII are inhibitors [75]. 
TGRLPs bind and stabilise LPL and protect it from angptl-4 inhibition; apo-CI and CIII inhibit this 
stabilisation [75]. Apo-E inhibits [76] and apo-AV stimulates [77] LPL and plasma TAG clearance. 
The physiological role of these effects is currently uncertain, but support the concept of TGRLPs 
regulating LPL and their own disposal.  
Naturally-occurring low LPL-activity mutants including mink (Mustela vison) and domestic cat (Felis 
catus) have hyperlipidema in both fed and fasted states [78], supporting significant cardiac TGRLP 
uptake. Human LPL deficiency patients have severe hypertriglyceridemia, with increased cardiac 
glucose uptake (as with mouse H-LPL-KOs [33]), but do not show cardiac dysfunction, suggesting 
TGRLPs are a major but not essential cardiac energy source [79]. Whole body LPL-KO leads to 
severe hyperlipidemia and neonatal death; however, expression of LPL solely in heart  was 
sufficient to prevent hypertriglyceridemia and lethality [18, 46]. Depletion of cardiac LPL by 
GPIHBP1-KO [64] or H-LPL-KO [60] also increased plasma TAG. LPL activity is required for TAG 
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sequestration within myocardial LDs  ? chemical inhibition of LPL or H-LPL deletion inhibited 
cardiac LD formation [80]. Augustus et al found rapid TAG clearance by mouse hearts 
(proportionately more than any other tissue examined) with broadly similar rates for synthetic 
CM-like TAG emulsion and VLDL-TAG utilisation [45]. Cardiac TAG uptake was highly dependent on 
LPL rather than receptor-dependent pathways: uptake was decreased by 88% in LPL-KO mice 
rescued with liver LPL, and heparin and the LPL inhibitor THL inhibited cardiac TAG uptake by 64% 
and 82% respectively (although residual uptake occurred through non-LPL mechanisms) [45]. In rat 
hearts, CM-TAG uptake was twice as rapid as VLDL-TAG, but both were inhibited to a greater 
extent by THL than by the LP receptor antagonist suramin [15]. Together, these studies support 
ƚŚĞƌŽůĞŽĨƚŚĞŚĞĂƌƚĂƐĂŶĞĨĨĞĐƚŝǀĞ ‘ƐŝŶŬ ?ĨŽƌƉůĂƐŵĂd'ĂŶĚƚŚŝƐŝƐƉƌŝŵĂƌŝůǇĂĨƵŶĐƚŝŽŶŽĨ>W>
lipolysis and not its bridging function. 
Less well characterised is the importance of LPL to cardiac performance. Mice lacking H-LPL 
survive, and cardiac function has been reported as normal in these mice [80]. However, NEFA or 
glucose alone may not be sufficient for optimal cardiac function [44]. Systolic dysfunction and 
hypertriglyceridemia were noted in H-LPL-KO mice [60, 81], and these mice failed to compensate 
for increased afterload [55]. Loss of H-LPL forced hearts to increase glucose utilisation [82], but  
available plasma NEFA are insufficient for optimum cardiac function, arguing that LPL-derived 
TAG-FAs are more important than NEFA for maintaining normal cardiac function. GLUT-1 
overexpression on a background of H-LPL deletion increased glucose utilisation and corrected 
cardiac energetics and rescued function [83]; similarly, increased lactate utilisation and NEFA 
availability in exercise-trained mice could partially compensate for H-LPL deletion and limited 
TGRLP utilisation [83]. Defective energy intake can therefore be a contributor to cardiac 
dysfunction, though carbohydrates may substitute for FA under certain conditions.  
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However, LPL depleted mouse hearts had altered gene expression characterised by decreased FA 
metabolism and increased glucose utilisation, associatĞĚǁŝƚŚĚĞĐƌĞĂƐĞĚWWZɲĂĐƚŝǀĂƚŝŽŶ ?
implying a more generalised effect on metabolism [33, 44]. A specific role for LPL in the release of 
WWZɲůŝŐĂŶĚƐŚĂƐƌĞĐĞŶƚůǇďĞĞŶƉƌŽƉŽƐĞĚ[84], suggesting that specifically VLDL-derived FAs 
ĂĐƚŝǀĂƚĞŵǇŽĐĂƌĚŝĂůWWZɲ-responsive genes to a greater extent than NEFA, by generating very 
high concentrations of unbound FA locally [85]. 
3.2. Lipoprotein receptor - mediated cardiac TAG uptake 
 
Receptor-mediated assimilation of TGRLP has been reported for many tissues including heart [15, 
60]; the principal cardiac lipoprotein receptor is believed to be the VLDL receptor (VLDLR), a highly 
conserved type 1 transmembrane glycoprotein member of the LDL receptor superfamily. It binds 
and internalises VLDL and other apo-E containing lipoproteins, including CM, in concert with LPL 
and apo-E (see [86-89]), suggesting VLDLR has a LPL-facilitating function. VLDLR is highly-expressed 
in tissues with high FA utilisation (i.e. a similar tissue distribution to LPL) including cardiomyocytes 
and to a limited extent endothelial cells [90] [91]. VLDLR is important for LD formation in 
cardiomyocytes as VLDLR knockdown diminishes LD-TAG [92]. Vldlr
-/-
 mice fed high fat diets show 
decreased (~35%) cardiac uptake of [
3
H]TAG [93] despite having no marked phenotype. VLDLR 
likely provides a significant route of glycerolipid uptake by heart [45] but its dependence on LPL 
status has been challenged [92], and vldlr
-/-
 mice do not show altered plasma LP levels, despite 
decreased LPL expression [94], although stressing FA metabolism in these animals by fasting or 
high fat feeding [95] or cross-breeding on a hyperlipidemic ob/ob [95] or ldlr
-/-
 [96] or lpl
-/+
 [88] 
background does reveal a hypertriglyceridemic phenotype. VLDLR may substitute for bulk cardiac 
TAG uptake in LPL-KO models, and mediate the uptake of lipoprotein remnant (including CM 
remnant) particles [86, 97], again facilitated by LPL and apo-E [87].  Hence VLDLR may provide an 
accessory function to LPL, facilitating TGRLP anchoring to LPL by increasing the affinity of 
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lipoproteins for endothelium and enhancing lipolysis and TAG assimilation. The increased (VLDL)-
TAG in VLDLR-KO mice was exacerbated when LPL was also partly deficient (vldlr
-/-
 crossed with 
lpl
+/-
), with halved VLDL turnover rates [88]. VLDLR deficient mice had low LPL levels [98] and 
inhibition of VLDLR with RAP (a folding and trafficking chaperone for VLDLR [99]) reduced LPL 
activity in wild type but not VLDLR-KO mice, suggesting VLDLR is required for normal LPL 
regulation. Cardiac VLDLR expression is increased during growth and fasting [100], with cardiac LD-
TAG accumulation, but this is accompanied by increased LPL, FAT/CD36, H-FABPpm, acyl-CoA 
synthase and long chain acyl-CoA dehydrogenase mRNAs, supporting a more generalised elevation 
in lipid metabolism rather than a specific rise in VLDLR-mediated TAG uptake alone [100]. By 
contrast, Jokinen et al [101] noted no effect of fasting on rat heart VLDLR expression.            
Interestingly, a 50% decrease in cardiac VLDLR expression occurs in STZ-diabetes, with decreased 
post-heparin plasma LPL activity together with hypertriglyceridemia, suggesting that this may 
represent a mechanism to diminish excessive flux of TGRLP into cardiomyocytes [102]. This is 
supported by conditions such as nephrosis which also increase plasma TAG concentrations and 
decrease VLDLR [103]. Ventricular VLDLR expression is decreased in hypertrophy 
[104](spontaneously hypertensive rat, together with decreased LPL expression), consistent with 
decreased FA (and increased glucose) utilisation [1], but no change in VLDLR in rat hearts 
subjected to increased workload (aortic constriction [105] or cold acclimation [57] -induced) was 
seen (despite increased cardiac LPL). In experimental sepsis, endotoxin decreased both cardiac 
VLDLR (via IL-1 ɴ ?expression and lipid accumulation in fasting mice; downregulation of VLDLR 
expression by LPS was mediated by IL-1ɴ [106]. VLDLR is upregulated in hypoxic/ischemic 
conditions in rodent cardiomyocytes, hearts, and human hearts, via HIF-1ɲ and (non-classical) HRE 
in the VLDLR promoter [92, 107, 108] with increased VLDL uptake and myocellular lipid 
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accumulation [108], and this mechanism may contribute to the TAG accumulation observed in 
hypoxia [109, 110].  
4. Myocardial intracellular triacylglycerol utilisation 
Intracellular cardiomyocyte TAG (mTAG) is a source of glycerolipids for structural/membrane (e.g. 
phospholipid) and signalling (e.g. DAG) functions [111], and mTAG-derived FAs may be metabolic 
signals/PPAR ligands [112](Fig. 1). mTAG buffers excess, potentially toxic FAs (especially at times of 
increased NEFA flux-uptake and/or limited FA oxidation), hence its putative role in lipotoxicity 
[113, 114]. However, its utilisation for ATP synthesis depends on oxidative metabolism, and the 
oxygen required for this must be derived from the coronary blood  ? this raises a paradox, since if 
blood flow is sufficient to provide oxygen for mTAG-FA oxidative metabolism, then it should also 
be able to provide blood-borne substrates. This discussion will focus specifically on mTAG as an 
oxidative substrate.  
Studies specifically examining mTAG as an energy substrate are scarce, but an important role for 
mTAG as an oxidative substrate is emerging. Most exogenous FAs are rapidly oxidised by the 
cardiomyocyte [15, 16], and substantial cycling through mTAG prior to oxidation would require 
that mTAG synthesis and lipolysis are very active pathways, (see [111, 115]); indeed the concept of 
mTAG-FA pool turnover now appears to be central to its physiological role in energy provision as 
well as cardiac disease. The lipid droplet, previously considered an inert pool of storage TAG, is 
now known to be a highly dynamic FA resource (see [116, 117]), a major contributor to basal 
myocardial oxidation, and essential for normal cardiac function [118]. Myocardium shows the 
fastest TAG turnover of any tissue (see [119]), and this appears to be PPAR-driven [120]. Mouse 
heart TAG turnover rate actually exceeds the rate of FA oxidation, suggesting that most exogenous 
FAs are cycled through intracellular TAG prior to oxidation [120](supporting earlier findings of 
cardiac TAG-FA provision [121]). This may serve to protect the myocardium from excessive PPAR 
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activation from FA-CoA esters (putative PPAR ligands) and maintain myocardial metabolic 
flexibility and endogenous substrate mobilisation (e.g. on adrenergic stimulation [122]). mTAG as 
an energy resource is facilitated by the proximity of the LD to mitochondria [123]. The LD 
resembles plasma lipoproteins in structure, comprising a phospholipid monolayer shell containing 
multiple lipases, regulatory and scaffold proteins [119] related to core lipid metabolism, and a 
hydrophobic core [117]. Myocardial LDs are small with large surface areas facilitating rapid TAG 
mobilisation, and LD-TAG pathways are associated with the outer mitochondrial membrane and 
this may be related to intracellular channelling. 
4.1. Myocardial triacylglycerol synthesis 
Glycerol phosphate acyltransferase (GPAT) initiates TAG synthesis and is rate-limiting for this 
pathway. GPAT1 and GPAT2 are both expressed in cardiac outer mitochondrial membranes whilst 
GPAT3 and GPAT4 are found in the SR [115]. Cardiac GPAT activity and increases with fasting - 
likely a mechanism to buffer incoming FAs and/or to act as an internal FA ƐƚŽƌĞĨŽƌƐƵďƐĞƋƵĞŶƚɴ-
oxidation [124]. Interestingly, cardiac GPAT activity also increases with adrenergic stimulation 
[125] potentially increasing TAG-&ĂǀĂŝůĂďŝůŝƚǇĨŽƌɴ-oxidation by increasing TAG pool turnover 
during increased cardiac work. Paradoxically, augmenting mTAG synthesis (by over-expression of 
diacylglycerol acyltransferase (DGAT-1)) promotes FA oxidation [113] (and lipolysis of mTAG 
directly releases FA for oxidation [120, 126]) implying that a TAG pool is required to promote FA 
oxidation and pool size may be critical. Hence TAG turnover is intimately related to FA oxidation. 
Interestingly, depletion of TAG synthetic capacity (by lipin-1/PAP depletion) causes less mTAG 
lipolysis and hence less reliance on mTAG for energy in FA-free perfusions [127]. 
4.2. Myocardial triacylglycerol lipolysis  
Recent advances elucidating the mechanism of LD-mTAG hydrolysis have yielded important 
insights into the function of cellular TAG. Adipose triglyceride lipase (ATGL; PNPLA2; desnutrin; 
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calcium-ŝŶĚĞƉĞŶĚĞŶƚW> ?ɺ[128, 129]) is rate-limiting for the mobilisation of mTAG for ɴ-
oxidation. ATGL expression is increased by FAs, exercise, high fat feeding [130], starvation [131] 
and STZ-diabetes [132] suggesting that plasma-derived FAs activate lipolysis. However, ATGL 
activity may also be inhibited by long chain FA-CoA [133]  ? possibly a protective feedback 
mechanism preventing lipotoxic damage [134]{Pulinilkunnil, 2013 #25389}. ATGL-deficient mouse 
hearts have increased mTAG, together with increased glucose utilisation and cardiac dysfunction 
[129, 135, 136], implying that defective mTAG-FA provision may impair cardiac energetics. Loss of 
activity mutations in human ATGL cause neutral lipid storage disease, with cardiomyopathy [137]. 
Moreover, WWZɲĂŶĚWWZɷŐĞŶĞĞǆƉƌĞƐƐŝŽŶĂƌĞĚŽǁŶƌĞŐƵůĂƚĞĚin rodent ATGL deficiency [112], 
presumably due to decreased FA-PPAR ligands [135, 136], and this is associated with impaired 
mitochondrial oxidation [112], supporting the role of mTAG-derived FAs as oxidative substrates 
together with significant shuttling of incoming FAs through the LD-TAG pool prior to lipolysis and 
FA release for ɴ-oxidation [120, 126, 138]. Heart-specific ATGL overexpression decreased mTAG, 
and surprisingly, decreased cardiac FA oxidation, supporting a role for a mTAG pool to facilitate FA 
flux to mitochondria.  In addition, improved cardiac systolic function and protection from 
pressure-overload stress remodelling was seen in older mice overexpressing ATGL [114]. ATGL 
overexpression maintained cardiac energetics (ATP; PCr:ATP) and function in high fat fed mice, but 
exogenous NEFA oxidation was halved, suggesting preferential utilisation of endogenous lipids 
from the mTAG pool [139]. Perilipin-5 (PLIN5) binds ATGL on the LD surface [140], shielding TAG 
from lipolysis; ectopic PLIN5 expression increased mTAG levels and decreased FA oxidation, again 
suggesting rates of FA oxidation may be determined by mTAG-FA turnover [141, 142]. PLIN5 is also 
present on mitochondria, where it facilitates the tightly-coupled association of mitochondria with 
LDs [141], controlling both LD-TAG-derived FA release and facilitating its delivery to mitochondria 
for ɴ-oxidation [141, 143, 144]. Together, these observations indicate that mTAG pool turnover 
may dictate rates of FA oxidation as the majority of FA cycles through mTAG. Therefore factors 
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that modulate the mTAG pool size may ultimately dictate rates of FA oxidation without directly 
affecting mitochondrial function. 
4.3. Myocardial triacylglycerol-fatty acid oxidation 
Measurements of myocardial TAG-FA oxidation have been attempted by a variety of techniques, 
including: 1. estimates based on changes in mTAG content 2. difference estimates based on total 
and exogenous FA oxidation and mVO2 measurements 3. pulse-chase radiolabelling experiments 
and 4. NMR techniques, estimating TAG pool turnover.  
General evidence for the importance of mTAG in FA provision for oxidation and efficient cardiac 
metabolism is the huge (>20 fold) increase in mTAG seen in inborn errors [145, 146] and mouse 
models [146, 147] of defective mitochondrial ɴ-oxidation, especially as this is associated with 
cardiac dysfunction. Similar observations were noted for human subjects with neutral lipid storage 
disease [137]. 
A compelling demonstration of the importance of mTAG in energy provision is seen in ex vivo 
working rat hearts subject to acute increases in workload. Increased  “ĞǆĞƌĐŝƐĞ ? ?ǁŽƌŬ ?ŝŶĐƌĞĂƐĞĚ
ƚŽƚĂůɴ-oxidation (mVO2) due to increased FA availability from both exogenous ([3H]-oleate) and 
endogenous (calculated) sources ? in exercise there was increased mTAG oxidation with no change 
in mTAG content  ? implying TAG turnover increased [148]. Exercise produces a switch to mTAG as 
energy substrate (mTAG oxidation increasing from about 10% of total FA oxidation to about 20% 
during contractile stimulation); in addition, lactate may also be permissive in this state, high 
lactate stimulating TAG turnover [149]. Subsequently, indirect estimates of mTAG oxidation found 
that mouse hearts lacking functional ACC2 had increased exogenous NEFA oxidation (22%) but 
also decreased mTAG content (and normal LV systolic function); however, mVO2 measurements 
suggested increased oxidation of mTAG [150]. Hence, removing the inhibition of FA flux through 
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CPT1 facilitated utilisation of mTAG for FA oxidation ĂƐĂĐŽŵƉŽŶĞŶƚĨŽƌŝŶĐƌĞĂƐĞĚ ‘ŐůŽďĂů ?& 
oxidation in the heart. 
Pulse-chase radiolabelling experiments provide direct evidence for the importance of mTAG to 
cardiac ɴ-oxidation, with two thirds of 14C-labelled mTAG utilised by rat hearts in the absence of 
exogenous FA; addition of NEFA preserved most (though not all  ? about 65%) of the labelled 
mTAG, indicating that endogenous mTAG makes a significant contribution to myocardial oxidative 
metabolism [151]. Catecholamines stimulated mTAG lipolysis and oxidation [152, 153], but only in 
the absence of exogenous NEFA [153, 154], and mTAG oxidation increased with cardiac work in 
the same model [154].  
mTAG and exogenous NEFA oxidation were measured in mTAG-prelabelled working hearts 
perfused with no, low (0.4mM), or high (1.2mM) concentrations of palmitate. Endogenous mTAG 
oxidation rates were high (nearly one half of maximal NEFA oxidation rates; ~60% of myocardial 
ATP synthesis) in the absence of NEFA, with corresponding loss of mTAG content, but mTAG 
oxidation rate was suppressed and mTAG stores maintained when NEFA (1.2mM) was available. 
Interstingly, mTAG still contributed 12-20% of total FA oxidation, representing ~11% of cardiac ATP 
synthesis, indicating the obligate nature of mTAG for ATP production [126]. Furthermore, under 
these conditions loss of 
14
C label from the [
14
C]mTAG pool was matched by incorporation of 
3
H 
label from exogenous [
3
H]NEFA, indicating conservation of mTAG pool turnover and size. 
Interestingly, the initial mTAG oxidation rate was higher than subsequent rates [126, 155, 156], 
suggesting multiple intracellular TAG pools. 
Recently, NMR techniques have provided important insights into myocardial TAG metabolism and 
pool dynamics in humans, confirming findings in animal models of metabolic disease [157, 158]. 
Dynamic mode NMR using 
13
C-palmitate shows an initial, saturable exponential incorporation into 
mTAG in the intact heart, representing sarcolemmal receptor-mediated FA uptake, and a slower 
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linear rate, determined by the rate of cellular metabolism and sensitive to inhibitors of LCFA 
metabolism, reflecting TAG turnover [118, 120, 159-161]. TAG pool turnover is a function of mTAG 
pool size and FA availability: TAG turnover increases with high fat diet (in association with 
increased DGAT1 and ATGL expression [120, 130]), in diabetes [160] ĂŶĚŝŶWWZɲĂŶĚW' ?ɲ
overexpressing mouse hearts [120, 162], but is decreased in cardiac hypertrophy with diminished 
PPAR activity [118]. In mouse hearts mTAG pool turnover measured by 
13
C-NMR was 3.75 times 
faster than palmitate oxidation, suggesting that palmitoyl units for oxidation were preferentially 
derived from cellular TAG rather than exogenous NEFA (and hence exogenous FAs must first be 
routed through the TAG pool)[120]. Mouse hearts over-expressing PPARɲ (a model with diabetic-
like phenotype) had even higher rates of mTAG pool turnover compared to (similar) exogenous 
NEFA oxidation rates (12.5-fold faster), implying that almost all incoming FAs are channelled 
through TAG; the mTAG pool size was comparable, but enzymes of TAG synthesis were increased 
in line with the increased TAG pool turnover rates [120]. This suggests that TAG pool turnover rate 
is more important than tissue TAG content for cardiomyocyte FA metabolism; both exogenous FA 
and TAG contribute to the accessible pool of cellular FA-CoA. Therefore, LD-mTAG  turnover 
couples and matches FA uptake to utilisation through both TAG synthesis and lipolysis, regulating 
energy provision and potentially cardiac function [118, 161, 163]. Failure of this dynamic 
relationship between exogenous FA metabolism and lipid deposition is a potential cause of the 
maladaptive changes that contribute to cardiac dysfunction [164].  
4.4. Myocardial triacylglycerol oxidation and cardiac disease: 
To date, limited information only is available on the role of mTAG as an oxidative substrate in 
cardiac disease. Myocardial lipid accumulation with decreased FA oxidation in heart failure [1] 
suggests optimal cardiac function requires mTAG energy provision, although caution is required 
with this interpretation since diabetes is associated with increased mTAG, ATGL expression and FA 
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oxidation, but also cardiac dysfunction [132, 156, 165, 166]. TAG turnover is uncoupled from 
energy demand in heart failure [118, 163]. With rat aortic banding, mTAG-FA oxidation was 
decreased to zero in early hypertrophy/failure, in line with decreased mTAG pool turnover (and 
mTAG content), and increased glucose oxidation; NEFA oxidation was not increased to 
compensate the decreased mTAG oxidation [118]. Adrenergic stimulation doubled mTAG 
oxidation in proportion to workload in healthy hearts, but not in failing hearts (which had lower 
mTAG turnover rates relative to cardiac work), with the proportion of TAG metabolism to ATP 
production unchanged (about 10% - similar to [126])[118]; since FA oxidation decreases in 
response to adrenergic stimulation in heart failure, it is likely that abnormalities of cellular FA 
oxidation are early events in the development of cardiac dysfunction.   
mTAG has also been shown to be an important energy source during reperfusion [167, 168]. 
Turnover rates of mTAG (based on glycerol measurements) increased during ischemia, but 
decreased on reperfusion [168]. Rat hearts reperfused in the presence of high (1.2mM, 
pathologically relevant) NEFA had increased NEFA oxidation rates, but only an initial increase in 
mTAG-FA oxidation; mTAG lipolysis was unchanged but mTAG synthesis was increased, expanding 
the mTAG pool and potentially protecting against toxic intracellular FAs [155]. In the absence of 
NEFA, mTAG oxidation increased on reperfusion and this was associated with improved functional 
recovery [155], suggesting that mTAG-derived FAs do not contribute to IR injury, as has been 
suggested for exogenous FA (though potentially arguing against incoming NEFAs having to 
obligatorily turnover through the TAG pool, at least in reperfusion). Increased mTAG content and 
turnover (induced by DGAT1 overexpression) were associated with normal cardiac energetics and 
function, but in the presence of exogenous NEFA, increased mTAG turnover was cardioprotective 
following ischemia, with improved function during reperfusion [169]. 
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Diabetes is characterised by increased cardiac FA metabolism, with increased mTAG content [156, 
165, 170] and impaired LV function [170]. TAG increases in diabetic hearts on acute fasting 
accompany diastolic dysfunction [171], though prolonged fasting improves insulin sensitivity, 
decreases mTAG and improves cardiac function, suggesting a diversion of TAG-derived FA to ɴ-
oxidation [172]. However, rates of mTAG oxidation in diabetic hearts have been reported as 
similar to controls [156, 165], suggesting that associated elevated NEFA concentrations may 
increase mTAG pool size but have only modest effects on mTAG pool turnover. STZ-diabetic rat 
hearts have increased mTAG content and turnover when perfused with high NEFA (1.2mM 
palmitate); at lower NEFA (0.5mM) concentrations, diabetic hearts still have increased TAG 
turnover, but mTAG content is unchanged [160]. mTAG oxidation contributed about 16% of ATP 
synthesis in diabetes, but surprisingly no contribution of mTAG to mitochondrial ATP synthesis was 
found in healthy hearts [160] (basal mTAG oxidation in healthy hearts accounted for only about 
10% of total ATP synthesis, in good agreement with previous findings [126, 173]). Fractional 
enrichment of TAG was lower in diabetic hearts, suggesting TAG compartmentalisation in the 
diabetic myocardium (other reports have also suggested multiple TAG compartments with 
different turnover rates [126, 151, 174, 175]). STZ-diabetic rat hearts had increased mTAG content 
and lipolysis, but unchanged mTAG oxidation compared to controls (mTAG oxidation contributing 
about 10% of ATP production in control and diabetic hearts) when perfused with 1.2mM 
palmitate; however, in the absence of NEFA, mTAG oxidation increased in diabetic myocardium, 
providing some 70% of ATP synthesis [173]. Non-obese type 2 diabetic (GK) rats also have 
increased mTAG, and LV dysfunction; FA metabolism (assessed by PET) was increased, mostly a 
result of increased FA oxidation from mTAG, since genes of both TAG synthesis and lipolysis were 
increased [28]. 
5. Concluding remarks: 
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It is finally emerging that TAGs are indeed major providers of cardiac energy; furthermore, 
alterations in myocardial TAG utilisation are clearly associated with impaired cardiac function. 
However, outstanding questions remain, including the teleological role of VLDL as a FA carrier and 
NEFA substitute (i.e. VLDL as a metabolic signal), the regulation of myocardial LPL activity in 
relation to metabolic (and particularly plasma TAG) status, the possibility of differential uptake 
pathways and intracellular channelling of FAs from different sources (NEFA; CM-TAG; VLDL-TAG), 
together with the requirement for incoming FAs to cycle through mTAG before oxidation. In 
particular, defining the precise mechanism(s) of myocellular FA assimilation, together with the 
extent to which TGRLP-derived FAs contribute to mTAG pool turnover, compared to the 
requirement of NEFA to cycle through mTAG (hence putative intracellular FA channelling streams) 
remains a challenge. 
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Figure legends: 
Figure 1. Utilisation of triacylglycerol (TAG) by the cardiomyocyte. Triacylglycerol is available for 
ŵŝƚŽĐŚŽŶĚƌŝĂůɴ-oxidation from exogenous supply (CM: chylomicrons; VLDL: very-low-density 
ůŝƉŽƉƌŽƚĞŝŶ ?ĂŶĚĞŶĚŽŐĞŶŽƵƐŵǇŽĐĂƌĚŝĂů “ƐƚŽƌĞƐ ? ?ŵd' ?ǁŝƚŚŝŶůŝƉŝĚĚƌŽƉůĞts. Current 
controversies include (1) the degree to which fatty acid (FA) for oxidation is supplied from these 
various sources, in competition with non-esterified FA (NEFA), in the normal and diseased heart 
(2) the respective importance of lipoprotein receptor (VLDL-R)-mediated and LPL-mediated 
exogenous TAG uptake (3) the specific uptake route for FA derived from lipoprotein lipase (LPL)-
ŵĞĚŝĂƚĞĚd'ůŝƉŽůǇƐŝƐĂŶĚƚŚĂƚŽĨE& ?ĨĂĐŝůŝƚĂƚĞĚƵƉƚĂŬĞŽƌ “ĨůŝƉ-ĨůŽƉ ?&ƚƌĂŶƐůŽĐĂƚŝŽŶĂĐƌŽƐƐ
the sarcolemma), and whether these are shared or separate (4) the existence of distinct 
intracellular FA pools derived from the various FA sources and uptake mechanisms (5) the extent 
to which intracellular FAs must be obligatorily cycled through intracellular mTAG prior to 
utilisation as respiratory fuel, or signalling and structural functions. Lipid droplet and mitochondria 
are in close anatomical and functional proximity. EC: endothelial cell; DAG: diacylglycerol; GPAT: 
glycerol-phosphate acyltransferase; DGAT: diacylglycerol acyltransferase; ATGL: adipose 
triacylglycerol lipase; PLIN5: perilipin-5; PPAR: peroxisome proliferator-activated receptor; VLDLR: 
VLDL-receptor; FATP: fatty acid transport protein; FAT: fatty acid translocase; FABP: fatty acid 
binding protein. 
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Figure 1 
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Highlights for Review: Evans & Hauton BBALIP-16-36 
 
 
 
Highlights: 
x Triacylglycerols are supplied to the myocardium within chylomicrons and VLDL 
x Heart assimilates triacylglycerol-rich lipoproteins by LPL and receptor-mediated routes 
x Exogenous triacylglycerol-derived fatty acids enter an intracellular lipid pool 
x Intracardiac triacylglycerol is an important source of fatty acids for oxidation 
x Dysregulation of triacylglycerol metabolism is associated with cardiac dysfunction 
